Arrowhead Research Corporation（ARWR）今日盘中大涨26.10%，成为纳斯达克生物技术指数中的领涨股之一。
消息面上，TD Cowen分析师在报告中指出，ARWR虽然报告了2025财年的亏损，但公司势头强劲，其新药Redemplo（用于治疗家族性乳糜微粒血症综合征）已成功上市。此外，分析师还提到，公司关于肥胖症资产的初步数据将于明年1月初公布，进一步提振了市场信心。生物技术板块近期表现强劲，纳斯达克生物技术指数本季度已上涨约19%，ARWR的突出表现也反映了市场对其创新管线的乐观预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.